Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad

Mol Cancer Ther. 2005 Apr;4(4):603-11. doi: 10.1158/1535-7163.MCT-04-0107.

Abstract

Trichostatin A produces predominantly G(1) cell-cycle blockade and differentiation of the cisplatinum-sensitive A2780 ovarian cancer cell line. Given the propensity of ovarian tumors to become resistant to cisplatinum, often leading to cross-resistance to other agents, we have extended these observations by examining how the emergence of resistant phenotypes in A2780 cells affects the actions of histone deacetylase (HDAC) inhibitors. Trichostatin A exposure (100 ng/mL, 24 hours) induced ultrastructural differentiation of the "intrinsically" cisplatinum-resistant A2780-9M subline, with the reappearance of intercellular junctions and lumina containing primitive microvilli. Similar trichostatin A exposure in the acquired resistance A2780CP cells produced minimal differentiation consisting of occasional weak intercellular junctions. Independent of the differences in trichostatin A-induced differentiation, in both resistant sublines trichostatin A produced a similar reduction in cell viability, by >90%, within 5 days of treatment. Diminished viability in both A2780-9M and CP cells was associated with the absence of cell cycle arrest in G1, resulting in predominant G2-checkpoint arrest accompanied by a 10- to 20-fold increase in Annexin V binding and the reemergence of apoptosis. Similar cell cycle arrests and apoptosis were also observed using other HDAC inhibitors and in other resistant ovarian cancer cell lines (OVCAR-3 and SK-OV-3). Trichostatin A-induced apoptosis in resistant cells is in sharp contrast to its effects on the parental cisplatinum-sensitive A2780 and normal MRC-5 fibroblast cell lines (predominant cycle arrest in G1 with no detectable apoptosis). Western immunoblot analysis indicated trichostatin A triggers apoptosis in resistant ovarian cancer cells via p53-independent activation of the intrinsic "mitochondrial" pathway, commensurate with induction of the Bcl-2-related protein Bad. These results suggest cisplatinum resistance alters the effects of HDAC inhibition through a shift in cell cycle arrest from the G1 to the G2 checkpoint and reactivation of the intrinsic mitochondrial apoptotic cascade.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Annexin A5 / chemistry
  • Annexin A5 / metabolism
  • Antineoplastic Agents / pharmacology*
  • Apoptosis*
  • Blotting, Western
  • Carrier Proteins / biosynthesis*
  • Cell Differentiation
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Survival
  • Cisplatin / pharmacology*
  • Female
  • Fibroblasts / metabolism
  • Flow Cytometry
  • G1 Phase
  • G2 Phase
  • Histone Deacetylase Inhibitors*
  • Humans
  • Hydroxamic Acids / pharmacology
  • Immunohistochemistry
  • Microscopy, Electron
  • Mitochondria / metabolism*
  • Mitosis
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / metabolism*
  • Phenotype
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
  • Time Factors
  • bcl-Associated Death Protein

Substances

  • Annexin A5
  • Antineoplastic Agents
  • BAD protein, human
  • Carrier Proteins
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-Associated Death Protein
  • trichostatin A
  • Cisplatin